Precigen (PGEN) Total Liabilities (2012 - 2026)
Precigen (PGEN) posted quarterly Total Liabilities of $118.4 million for Q1 2026, up 4.47% year-over-year from $113.3 million in Q1 2025, and down 12.04% quarter-over-quarter from $134.6 million in Q4 2025.
Precigen (PGEN) Total Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Total Liabilities for 15 consecutive years, with $118.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 4.47% year-over-year to $118.4 million; the TTM figure through Mar 2026 stood at $118.4 million (up 4.47% YoY), while the FY2025 annual figure was $134.6 million, up 71.38% from the prior year.
- Total Liabilities slipped to $118.4 million in Q1 2026 per PGEN's latest filing, from $134.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $265.6 million in Q2 2022 and bottomed at $28.1 million in Q3 2024.
- Historically, Total Liabilities has averaged $99.2 million across 5 years, with a median of $89.7 million in 2022.
- Annual changes were most pronounced in 2023 — Total Liabilities tumbled 84.44% — and 2025, when it jumped 360.52%.
- Precigen's Total Liabilities stood at $89.7 million in 2022, then plunged by 63.73% to $32.5 million in 2023, then jumped by 141.31% to $78.5 million in 2024, then jumped by 71.38% to $134.6 million in 2025, then decreased by 12.04% to $118.4 million in 2026.
- Business Quant data shows PGEN's Total Liabilities at $118.4 million in Q1 2026, $134.6 million in Q4 2025, and $129.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 126.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.72 Mn |
| Mar 31, 2026 | 118.39 Mn |
| Dec 31, 2025 | 134.59 Mn |
| Sep 30, 2025 | 129.40 Mn |
| Jun 30, 2025 | 107.79 Mn |
| Mar 31, 2025 | 113.33 Mn |
| Dec 31, 2024 | 78.54 Mn |
| Sep 30, 2024 | 28.10 Mn |
| Jun 30, 2024 | 29.99 Mn |
| Mar 31, 2024 | 37.83 Mn |
| Dec 31, 2023 | 32.55 Mn |
| Sep 30, 2023 | 43.01 Mn |
| Jun 30, 2023 | 41.32 Mn |
| Mar 31, 2023 | 57.41 Mn |
| Dec 31, 2022 | 89.72 Mn |
| Sep 30, 2022 | 116.71 Mn |
| Jun 30, 2022 | 265.57 Mn |
| Mar 31, 2022 | 261.73 Mn |
| Dec 31, 2021 | 252.51 Mn |
| Sep 30, 2021 | 245.65 Mn |